A CU Medicine provider.

I believe in finding the best, most cutting edge treatments to personalize care for my patients

Dr. Pollyea received his MD degree from the University of Chicago Pritzker School of Medicine. He stayed at the University of Chicago Hospital for his residency in Internal Medicine and served as Chief Medical Resident at Cook County Hospital. He then completed his fellowship training in Hematology and Oncology at Stanford University, where he also completed a Masters degree in Epidemiology with an emphasis on biostatistics and clinical trial design. In 2011 he came to the University of Colorado where he is currently the Clinical Director of Leukemia Services. Dr. Pollyea has served as the Principal Investigator of multiple early-phase clinical trials, and has received funding for his work from the American Society of Hematology, the American Society of Clinical Oncology and the Leukemia and Lymphoma Society. He has over 80 peer-reviewed publications and has spoken at many national and international meetings.


Monday: 7am - 5:30pm
Tuesday: 7am - 5:30pm
Wednesday: 7am - 5:30pm
Thursday: 7am - 5:30pm
Friday: 7am - 5:30pm
Saturday: Closed
Sunday: Closed

Qualifications and experience

Hematology, Internal Medicine, Medical Oncology, Blood / Lymphatic System - Blood Disorders, Cancers - Leukemia (Adult Acute), Cancers - Leukemia (Adult Chronic), Cancers - Lymphoma, Blood / Lymphatic System, Cancers
Languages spoken
Stanford University Program (2010)

Medical School
University of Chicago Division of the Biological Sciences The Pritzker School of Medicine (2003)

University of Chicago Program (2006)

John H Stroger Hospital of Cook County Program (2007)

Indiana University–Bloomington (IN) (1999)

Stanford University (2011)

Clinical interest for patients

Optimal management of leukemias and their complications

Research interest for patients

Dr. Pollyea’s research interests involve developmental therapeutics for myeloid malignancies (myelodysplastic syndromes and acute myeloid leukemia) through collaborative laboratory-based efforts and clinical trials involving novel therapies that he designs and leads. He is interested in developing drugs that target leukemia cells that will allow for definitive and curative therapies.

UCHealth strongly encourages you to consult with your health insurer to determine accurate information about your coverage and benefits for a particular health care service provided at a UCHealth facility. Read more here.